Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a class of anti-infectives called lipopeptides. Cubist also has an agreement with Optimer Pharmaceuticals, Inc. to co-promote Optimer's drug, DIFICID™ (fidaxomicin), in the U.S. as a treatment of Clostridium difficile-associated diarrhea (CDAD). The Cubist clinical product pipeline currently consists of a Phase 3 program focused on the development of a novel cephalosporin to address certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms and a Phase 2 program for the treatment of CDAD. Cubist also is working on several pre-clinical programs being developed to address areas of significant medical needs. These include therapies to treat various serious bacterial infections and agents to treat acute pain.
Cubist is dedicated to Diversity Inclusion, Diversity Hiring and Diversity Jobs.
no jobs found